Uticia Belfield, MD
Internal Medicine · Newburgh, NYNPI 1235369042
Payments from drug & device makers
Across 430 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$855
- Novo Nordisk$576
- Exact Sciences$558
- Boehringer Ingelheim$536
- Pfizer$525
- plus $4K from 25 others
What the payments were for
- Food & beverage$8,192100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 94 | $1,581 |
| GSK | 36 | $855 |
| Novo Nordisk | 37 | $576 |
| Exact Sciences | 21 | $558 |
| Boehringer Ingelheim | 27 | $536 |
| Pfizer | 26 | $525 |
| Lilly USA, LLC | 28 | $517 |
| AbbVie(2 entities) | 19 | $432 |
| Bayer | 15 | $333 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $332 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $329 |
| Johnson & Johnson | 16 | $285 |
| Otsuka America Pharmaceutical, Inc. | 10 | $225 |
| Axsome Therapeutics, Inc. | 8 | $174 |
| Astellas Pharma US Inc | 6 | $149 |
| Abbott | 7 | $144 |
| Novartis | 4 | $76 |
| Phathom Pharmaceuticals, Inc. | 4 | $75 |
| Biohaven Pharmaceuticals, Inc. | 3 | $63 |
| Amarin Pharma, Inc. | 4 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| Antares Pharma, Inc. | 2 | $48 |
| Merck | 3 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Amgen(2 entities) | 2 | $32 |
| Teleflex LLC | 1 | $31 |
| Medtronic | 1 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SHINGRIX$125
How this compares
$8,200 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 77 | $84,095 |
| EliquisApixaban | 58 | $76,604 |
| OzempicSemaglutide | 44 | $45,674 |
| JanuviaSitagliptin Phosphate | 24 | $39,713 |
| MounjaroTirzepatide | 37 | $38,033 |
| XareltoRivaroxaban | 15 | $22,168 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $19,823 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $17,056 |
| Spiriva RespimatTiotropium Bromide | 11 | $6,615 |
| Valsartan | 220 | $6,539 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 213 | $6,149 |
| Levothyroxine Sodium | 256 | $5,397 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,104 |
| SantylCollagenase Clostridium Hist. | 16 | $4,723 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $4,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $1,581 | $87,65893 claims |
| PfizerEliquis | $525 | $76,60458 claims |
| Novo NordiskOzempic | $576 | $45,67444 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $855 | $40,46763 claims |
| MerckJanuvia | $47 | $39,71324 claims |
| Lilly USA, LLCMounjaro | $517 | $38,03337 claims |
| Johnson & JohnsonXarelto | $285 | $22,16815 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $536 | $11,71922 claims |
| AbbVieSynthroid | $432 | $3,16553 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Newburgh
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.